Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus from eight brokerages (six buys, one hold, one sell) with an average 1‑year price target of $6.83.
• Several institutional investors increased stakes—Vanguard holds about 2.16M shares—and institutions/hedge funds collectively own 39.07% of the company.
• Pyxis recently beat expectations, reporting quarterly EPS of ($0.29) vs. ($0.35) expected and revenue of $11.04M vs. $0.13M expected; the stock trades near $2.30 with a ~$144.6M market cap.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $6.8333.

PYXS has been the topic of a number of research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Monday, April 13th. Stifel Nicolaus cut their price objective on Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, March 24th. Wedbush started coverage on Pyxis Oncology in a research note on Tuesday. They set an "outperform" rating and a $6.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, March 24th.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after buying an additional 9,062 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Pyxis Oncology by 37.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company's stock worth $58,000 after buying an additional 13,550 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company's stock worth $4,804,000 after buying an additional 14,566 shares in the last quarter. Velan Capital Investment Management LP grew its holdings in shares of Pyxis Oncology by 37.5% during the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company's stock worth $122,000 after buying an additional 15,000 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in shares of Pyxis Oncology by 150.7% during the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company's stock worth $40,000 after buying an additional 21,100 shares in the last quarter. Hedge funds and other institutional investors own 39.07% of the company's stock.

Pyxis Oncology Price Performance

PYXS opened at $2.30 on Thursday. The stock has a market cap of $144.57 million, a P/E ratio of -1.78 and a beta of 1.43. The firm has a fifty day moving average price of $1.57 and a 200 day moving average price of $2.34. Pyxis Oncology has a 1 year low of $0.97 and a 1 year high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $11.04 million during the quarter, compared to analysts' expectations of $0.13 million. Equities analysts expect that Pyxis Oncology will post -1.24 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.